Company intelligence / Profile preview

Kobayashi Pharmaceutical

Ownership: Private
Employees: ~3500
Development stage: Other

Overview

Kobayashi Pharmaceutical has a broad commercial portfolio focused on over-the-counter pharmaceuticals and consumer health products. It markets several small molecule drugs in Japan including celecoxib for osteoarthritis and post-operative pain. The company recently faced a major recall of cholesterol-lowering supplements containing red yeast rice due to safety concerns. No advanced clinical-stage pipeline was identified.

Therapeutic areas: RheumatologyOther
Modalities: Small moleculeDevice (for medical equipment and ventilators)Nutritional supplement
Industry: Food & Nutrition

Partnerships

Historical partnership with C.R. Bard Inc. for medical devices

Beyond the preview

Go deeper on Kobayashi Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kobayashi Pharmaceutical.

Explore the full profile